These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 23733481)
1. European drug agency's attempts to improve transparency stalled by legal action from two US drug companies. Dyer C BMJ; 2013 Jun; 346():f3588. PubMed ID: 23733481 [No Abstract] [Full Text] [Related]
2. The first 2 years of the European Medicines Agency's policy on access to documents: secret no longer. Doshi P; Jefferson T JAMA Intern Med; 2013 Mar; 173(5):380-2. PubMed ID: 23599918 [No Abstract] [Full Text] [Related]
3. Transparency interrupted: the curtailment of the European Medicines Agency's Policy on access to documents. Doshi P JAMA Intern Med; 2013 Nov; 173(21):2009-11. PubMed ID: 23959623 [No Abstract] [Full Text] [Related]
4. Bring me sunshine: EU drug companies make payments to doctors public. Jack A BMJ; 2013 Jul; 347():f4342. PubMed ID: 23833114 [No Abstract] [Full Text] [Related]
5. [The Medical Product Agency's work and economics--a comment]. Ahlqvist Rastad J; Salmonson T Lakartidningen; 2003 Jan; 100(5):345. PubMed ID: 12607382 [No Abstract] [Full Text] [Related]
6. Euro MPs refuse to approve medicines agency's accounts until they tighten rules on conflicts of interest. Watson R BMJ; 2012 May; 344():e3495. PubMed ID: 22597355 [No Abstract] [Full Text] [Related]
7. A tale of two transparency attempts at FDA. Tai L Food Drug Law J; 2013; 68(4):423-47, ii. PubMed ID: 24552081 [TBL] [Abstract][Full Text] [Related]
8. Predictable materiality: a need for common criteria governing the disclosure of clinical trial results by publicly-traded pharmaceutical companies. Cohen K; Cormier JW; Davar MV J Contemp Health Law Policy; 2013; 29(2):201-32. PubMed ID: 23837261 [No Abstract] [Full Text] [Related]
9. Drug companies will have to report all payments to US doctors from March 2014. Roehr B BMJ; 2013 Feb; 346():f826. PubMed ID: 23393117 [No Abstract] [Full Text] [Related]
10. European ombudsman questions European Medicines Agency over AbbVie redactions. Watson R BMJ; 2014 Nov; 349():g6904. PubMed ID: 25406123 [No Abstract] [Full Text] [Related]
11. Drug companies, doctors and disclosures. Tuorto S; Chan MK; Adusumilli PS Natl Med J India; 2004; 17(4):215-6. PubMed ID: 15372772 [No Abstract] [Full Text] [Related]
12. The European Medicines Agency's plans for sharing data from clinical trials. Groves T; Godlee F BMJ; 2013 May; 346():f2961. PubMed ID: 23657192 [No Abstract] [Full Text] [Related]
13. The International Conference on Harmonization common technical document--global submission format? Molzon JA Food Drug Law J; 2005; 60(3):447-51. PubMed ID: 16304749 [No Abstract] [Full Text] [Related]
14. Drugmakers prefer silence on test data; firms violate US law by not registering trials. Vedantam S Washington Post; 2004 Jul; ():A1, A4. PubMed ID: 15290815 [No Abstract] [Full Text] [Related]
16. Provision of information on regulatory authorities' websites. Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542 [TBL] [Abstract][Full Text] [Related]
17. Transparency lacking. Despite Sunshine Act rules, policies still an issue. Lee J Mod Healthc; 2013 Mar; 43(10):10-1. PubMed ID: 23593894 [No Abstract] [Full Text] [Related]
18. Glaxo agrees to post results of drug trials on web site. Harris G N Y Times Web; 2004 Aug; ():C4. PubMed ID: 15540364 [No Abstract] [Full Text] [Related]
19. The European Medicines Agency's strategies to meet the challenges of Alzheimer disease. Haas M; Mantua V; Haberkamp M; Pani L; Isaac M; Butlen-Ducuing F; Vamvakas S; Broich K Nat Rev Drug Discov; 2015 Apr; 14(4):221-2. PubMed ID: 25829266 [TBL] [Abstract][Full Text] [Related]
20. US to require public disclosure of drug and device industry's financial ties to doctors. Epstein K BMJ; 2012 Jan; 344():e515. PubMed ID: 22262802 [No Abstract] [Full Text] [Related] [Next] [New Search]